Native LDL-induced oxidative stress in human proximal tubular cells: Multiple players involved

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 2, 2011, Pages 375-395

  Piccoli, Claudia ^a   Quarato, Giovanni ^a   D'Aprile, Annamaria ^a   Montemurno, Eustacchio ^a   Scrima, Rosella ^a   Ripoli, Maria ^a   Gomaraschi, Monica ^b   Cirillo, Pietro ^a   Boffoli, Domenico ^a   Calabresi, Laura ^b   Gesualdo, Loreto ^a   Capitanio, Nazzareno ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Chronic kidney disease; Cytoplasmic phospholipase A2; Kidney proximal tubular cells; Lipid signalling; Low density lipoproteins; Mitochondria; NADPH oxidase; Reactive oxygen species; Redox signalling; ROS induced ROS release

Indexed keywords

CALCIUM; CYTOCHROME C; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ARTICLE; BIOSYNTHESIS; CALCIUM SIGNALING; CELL LINE; DRUG ANTAGONISM; DYSLIPIDEMIA; HUMAN; KIDNEY PROXIMAL TUBULE; METABOLISM; MITOCHONDRION; OXIDATIVE STRESS; PATHOLOGY; SIGNAL TRANSDUCTION;

CALCIUM; CALCIUM SIGNALING; CELL LINE; CYTOCHROMES C; DYSLIPIDEMIAS; HUMANS; KIDNEY TUBULES, PROXIMAL; LIPOPROTEINS, LDL; MITOCHONDRIA; NADPH OXIDASE; OXIDATIVE STRESS; PHOSPHOLIPASES A2; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 79951909095     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00946.x     Document Type: Article

References (57)

1. Kannel WB, Gordon T, Castelli WP. Role of lipid and lipoprotein fractions in atherogenesis: the Framingham Study. Prog Lipid Res. 1981; 20: 339-48.
2. Steinberg D, Parthasarathy S, Carew TE, et al Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989; 320: 915-24.
3. Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med. 1996; 20: 707-27.
4. Lee HS, Song CH. Oxidized Low-Density Lipoprotein and Oxidative Stress in the Development of Glomerulosclerosis. Am J Nephrol. 2009; 29: 62-70.
5. Saland JM, Ginsberg HN. Lipoprotein metabolism in chronic renal insufficiency. Pediatr Nephrol. 2007; 22: 1095-112.
6. Fogo AB. Mechanisms of progression of chronic kidney disease. Pediatr Nephrol. 2007; 22: 2011-22.
7. Cases A, Coll E. Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int Suppl. 2005; 99: S87-S93.
8. Kairaitis LK, Harris DCH. Tubularinterstitial interactions in proteinuric renal diseases. Nephrology. 2001; 6: 198-207.
9. Wardle EN. Cellular oxidative processes in relation to renal disease. Am J Nephrol. 2005; 25: 13-22.
10. Nistala R, Whaley-Connell A, Sowers R. Redox control of renal function and hypertension. Antioxid Redox Signal. 2008; 10: 2047-89.
11. Robinson KM, Janes MS, Beckman JS. The selective detection of mitochondrial superoxide by live cell imaging. Nat Protoc. 2008; 3: 941-7.
12. Brown GC. Control of respiration and ATP synthesis in mammalian mitochondria and cells. Biochem J. 1992; 284: 1-13.
13. Sumimoto H. Structure, regulation and evolution of Nox-family NADPH oxidases that produce reactive oxygen species. FEBS J. 2008; 275: 3249-77.
14. Cave AC, Brewer AC, Narayanapanicker A, et al NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal. 2006; 8: 691-728.
15. Li Y, Trush MA. Diphenyleneiodonium, an NAD(P)H oxidase inhibitor, also potently inhibits mitochondrial reactive oxygen species production. Biochem Biophys Res Commun. 1998; 253: 295-9.
16. Johnson DK, Schillinger KJ, Kwait DM, et al Inhibition of NADPH oxidase activation in endothelial cells by ortho-methoxy-substituted catechols. Endothelium. 2002; 9: 191-203.
17. Gill PS, Wilcox CS. NADPH oxidases in the kidney. Antioxid Redox Signal. 2006; 8: 1597-07.
18. Adam-Vizi V, Chinopoulos C. Bioenergetics and the formation of mitochondrial reactive oxygen species. Trends Pharmacol Sci. 2006; 27: 639-45.
19. Hawkins BJ, Madesh M, Kirkpatrick CJ, et al Superoxide flux in endothelial cells via the chloride channel-3 mediates intracellular signaling. Mol Biol Cell. 2007; 18: 2002-12.
20. Uchida S, Sasaki S. Function of chloride channels in the kidney. Annu Rev Physiol. 2005; 67: 759-78.
21. Levy R. The role of cytosolic phospholipase A2-alfa in regulation of phagocytic functions. Biochim Biophys Acta. 2006; 1761: 1323-34.
22. Rimessi A, Giorgi C, Pinton P, et al The versatility of mitochondrial calcium signals: from stimulation of cell metabolism to induction of cell death. Biochim Biophys Acta. 2008; 1777: 808-16.
23. 2+ concentration. Cell Calcium. 2001; 30: 311-21.
24. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev. 2007; 87: 99-163.
25. Porubsky S, Schmid H, Bonrouhi M, et al Influence of native and hypochlorite-modified low-density lipoprotein on gene expression in human proximal tubular epithelium. Am J Pathol. 2004; 164: 2175-87.
26. Zager RA, Johnson ACM, Hanson SY, et al Acute tubular injury causes dysreg-ulation of cellular cholesterol transport proteins. Am J Pathol. 2003; 163: 313-20.
27. 2+ channel subtypes and pharmacology in the kidney. Circ Res. 2007; 100: 342-53.
28. Kathryn JM, Freeman MW. Scavenger receptors in atherosclerosis beyond lipid uptake. Arterioscler Thromb Vasc Biol. 2006; 26: 1702-11.
29. Tanaka T, Nangaku M, Miyata T, et al Blockade of Calcium Influx through L-Type Calcium Channels Attenuates Mitochondrial Injury and Apoptosis in Hypoxic Renal Tubular Cells. J Am Soc Nephrol. 2004; 15: 2320-33.
30. Hirabayashi T, Murayama T, Shimizu T. Regulatory mechanism and physiological role of cytosolic phospholipase A2. Biol Pharm Bull. 2004; 27: 1168-73.
31. Mankelow TJ, Pessach E, Levy R, et al The requirement of cytosolic phospholipase A2 for the PMA activation of proton efflux through the N-terminal 230-amino acid fragment of gp91phox. Biochem J. 2003; 374: 315-9.
32. Finkel T. Oxidant signals and oxidative stress. Curr Opin Cell Biol. 2003; 15: 247-54.
33. Winterbourn CC. Reconciling the chemistry and biology of reactive oxygen species. Nat Chem Biol. 2008; 4: 278-86.
34. Naqui A, Chance B, Cadenas E. Reactive oxygen intermediates in biochemistry. Annu Rev Biochem. 1986; 55: 137-66.
35. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging and cancer: a dawn for evolutionary medicine. Annu Rev Genet. 2005; 39: 359-407.
36. Madamanchi NR, Runge MS. Mitochondrial dysfunction in atherosclerosis. Circ Res. 2007; 100: 460-73.
37. Zager RA, Johnson AC, Hanson SY. Proximal tubular cholesterol loading after mitochondrial, but not glycolytic, blockade. Am J Physiol Renal Physiol. 2003; 285: F1092-9.
38. Zorov DB, Filburn CR, Klotz LO, et al Reactive oxygen species (ROS)- induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes. J Exp Med. 2000; 192: 1001-14.
39. Brady NR, Hamacher-Brady A, Westerhoff HV, Gottlieb RA. A wave of reactive oxygen species (ROS)-induced ROS release in a sea of excitable mitochondria. Antioxid Redox Signal. 2006; 8: 1651-65.
40. Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial ROS-induced ROS release: an update and review. Biochim Biophys Acta. 2006; 1757: 509-17.
41. 2+]i through the mitochondrial ROS-PKCepsilon signaling axis in pulmonary artery smooth muscle cells. Free Radic Biol Med. 2008; 45: 1223-31.
42. Wosniak JJ, Santos CX, Kowaltowski AJ, et al Cross-talk between mitochondria and NADPH oxidase: Effects of mild mitochondrial dysfunction on angiotensin II mediated increase in Nox isoform expression and activity in vascular smooth muscle cells. Antioxid Redox Signal. 2009; 11: 1265-78.
43. Waring P. Redox active calcium ion channels and cell death. Arch Biochem Biophys. 2005; 434: 33-42.
44. Huser J, Blatter LA. Fluctuation in mitochondrial membrane potential caused by repetitive gating of the permeability transition pore. Biochem J. 1999; 343: 311-17.
45. 2+ release in isolated liver mitochondria. Biochim Biophys Acta. 1996; 1304: 129-38.
46. (2+)-dependent apoptosis through the mitochondrial pathway. J Biol Chem. 2004; 279: 25219-25.
47. Di Paola M, Zaccagnino P, Oliveros-Celis C, et al Arachidonic acid induces specific membrane permeability increase in heart mitochondria. FEBS Lett. 2006; 580: 775-81.
48. Cocco T, Di Paola M, Papa S, et al Arachidonic acid interaction with the mito-chondrial electron transfer chain promotes reactive oxygen species generation. Free Radic Biol Med. 1999; 27: 51-9.
49. 2+ currents via lysophosphatidylcholineinduced mitochondrial reactive oxygen species (ROS) production. Cardiovasc Res. 2006; 69: 855-64.
50. Cui XL, Ding Y, Alexander LD, et al Oxidative signaling in renal epithelium: Critical role of cytosolic phospholipase A2 and p38(SAPK). Free Radic Biol Med. 2006; 41: 213-21.
51. Kowaltowski AJ, Castilho RF, Vercesi AE. Mitochondrial permeability transition and oxidative stress. FEBS Lett. 2001; 495: 12-5.
52. Watanabe N, Zmijewski JW, Takabe W, et al Activation of Mitogen-Activated Protein Kinases by LysophosphatidylcholineInduced Mitochondrial Reactive Oxygen Species Generation in Endothelial Cells. Am J Pathol. 2006; 168: 1737-48.
53. Wang W, Fang H, Groom L, et al Superoxide flashes in single mitochondria. Cell. 2008; 134: 279-90.
54. 2+ response in human neuroblastoma SH-SY5Y cells. Life Sci. 2007; 80: 886-92.
55. Liu L, Barrett CF, Rittenhouse AR. Arachidonic acid both inhibits and enhances whole cell calcium currents in rat sympathetic neurons. Am J Physiol Cell Physiol. 2001; 280: 1293-305.
56. Fried LF. Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease. Kidney Int. 2008; 74: 571-6.
57. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008; 14: 37-44.